A thorough evaluation of each step of the #drugdevelopment process is the only way to be certain you’re free from nitrosamine contamination.

In its original advice to MAH’s, the European Medicines Agency warned manufacturers that it had identified 5 main root causes of formation and contamination. The risk from the raw materials, formation during the processing of the APIs, the use of certain solvents, reagents or catalysts, & indeed the use of recycled materials were featured as real risks.

By evaluating and then testing each individual material & step taken in the manufacturing process, you can correctly understand the influence of factors such as temperature change and solvent type used; each of which can have an impact and increase the amount of, or in some cases even cause, nitrosamines.  Only then you can be certain that the end product is safe and contamination free.

With the saga continuing to impact the pharma world, there has never been a more critical time to choose the correct partner.

Chartwell Actives LLC and QUINTA-ANALYTICA work together to offer a holistic approach to evaluating, performing risk-assessments, and running experimental testing for nitrosamines.

Additional News

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.